Neural NoiseBCI Weekly Brief (week of 2026-10-05)
This week’s signal is about interface durability and deployment plumbing: getting devices to the target, keeping recordings stable, and reducing calibration burden. The strongest items are still bounded evidence, with preprints, company-attributed updates, and animal or intraoperative models carrying most of the claims.
Research
SPDAlign: Interpretable Riemannian Alignment for EEG Forward Modeling Shifts
SPDAlign is relevant because EEG BCIs often fail at the boundaries between subjects, sessions, and sensor geometries. The preprint uses a forward-model framing and SPD-manifold alignment to reduce domain shifts without labeled calibration data, then evaluates on public EEG datasets; treat it as calibration-burden methods work, not a device result.
A soft bioelectronic system with a responsive hydrogel neural interface for direct force quantification and real-time intraoperative craniocerebral injury monitoring
This Nature Biomedical Engineering article is adjacent to BCI but technically relevant for cortical-interface safety instrumentation. The system combines pressure sensing, somatosensory evoked potentials, ECoG, and temperature monitoring, and the abstract says it was validated in rabbit brain-tumour excision models; the result belongs in the neural-interface stack, not as evidence for an assistive BCI.
Industry & News
Science Corp. announces 36-month PRIMA results
Science reports 36-month follow-up from PRIMAvera for its subretinal photovoltaic PRIMA visual prosthesis. The company says 27 patients were evaluable for safety and 18 for efficacy at 36 months, with no new safety signal between months 12 and 36 and a mean 29-letter ETDRS improvement; this is company-attributed clinical-trial follow-up, with PRIMA described by Science as commercially available in Europe and the UK and pending FDA approval in the US.
Paradromics reports four-year stable neural recording in sheep
Paradromics says two sheep implanted with cortical modules representative of its Connexus BCI electrode technology have shown more than four years of stable neural recording and decoding performance. The useful field signal is durability pressure on implanted BCI architectures; the limitation is equally important: this is company-released preclinical evidence, and the same release says Connexus is an investigational device limited by US law to investigational use.
Bridge Neurotech and Butterfly Network announce ultrasound BCI partnership
Bridge Neurotech and Butterfly Network announced a research and development agreement for a non-invasive BCI approach built around Butterfly’s programmable ultrasound-on-chip platform. The release says Bridge emerged from stealth, is enrolling its first human research study, and will license Butterfly technology under a multi-year agreement; this is a company-formation and platform bet, not validation that transcranial ultrasound decoding works as a deployed BCI.